ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have received a consensus rating of “Moderate Buy” from the seven analysts that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $18.83.

A number of analysts recently issued reports on the stock. Stifel Nicolaus restated a “hold” rating and set a $14.00 price objective (up previously from $10.00) on shares of ALX Oncology in a report on Friday, March 8th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a research note on Friday, April 12th. Finally, HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of ALX Oncology in a research report on Wednesday, April 10th.

ALX Oncology Stock Up 12.4 %

ALX Oncology stock opened at $14.49 on Wednesday. The firm has a market capitalization of $726.67 million, a PE ratio of -3.86 and a beta of 1.58. The company has a debt-to-equity ratio of 0.05, a current ratio of 5.24 and a quick ratio of 5.24. The company’s 50-day moving average is $13.50 and its 200-day moving average is $11.84. ALX Oncology has a fifty-two week low of $3.94 and a fifty-two week high of $17.42.

ALX Oncology (NASDAQ:ALXO) last released its quarterly earnings data on Thursday, March 7th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.09). Sell-side analysts anticipate that ALX Oncology will post -3.33 earnings per share for the current year.

Insider Activity at ALX Oncology

In other news, CEO Jason Lettmann acquired 4,400 shares of the company’s stock in a transaction on Thursday, March 14th. The stock was bought at an average cost of $11.31 per share, with a total value of $49,764.00. Following the completion of the purchase, the chief executive officer now directly owns 171,620 shares of the company’s stock, valued at $1,941,022.20. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other ALX Oncology news, CEO Jason Lettmann bought 4,400 shares of the firm’s stock in a transaction dated Thursday, March 14th. The stock was acquired at an average cost of $11.31 per share, for a total transaction of $49,764.00. Following the completion of the transaction, the chief executive officer now owns 171,620 shares in the company, valued at $1,941,022.20. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, insider Jaume Pons sold 20,000 shares of ALX Oncology stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $11.15, for a total value of $223,000.00. Following the sale, the insider now owns 628,359 shares of the company’s stock, valued at $7,006,202.85. The disclosure for this sale can be found here. 50.30% of the stock is currently owned by insiders.

Institutional Trading of ALX Oncology

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in ALX Oncology by 49.0% in the fourth quarter. Vanguard Group Inc. now owns 1,502,409 shares of the company’s stock worth $22,371,000 after purchasing an additional 494,173 shares in the last quarter. Wellington Management Group LLP purchased a new stake in shares of ALX Oncology during the fourth quarter worth about $1,201,000. American International Group Inc. grew its stake in shares of ALX Oncology by 24.1% during the fourth quarter. American International Group Inc. now owns 13,398 shares of the company’s stock worth $199,000 after acquiring an additional 2,600 shares during the last quarter. Price T Rowe Associates Inc. MD purchased a new stake in shares of ALX Oncology during the fourth quarter worth about $8,090,000. Finally, Legal & General Group Plc boosted its position in ALX Oncology by 42.6% in the fourth quarter. Legal & General Group Plc now owns 2,289 shares of the company’s stock valued at $34,000 after buying an additional 684 shares during the last quarter. 97.97% of the stock is currently owned by institutional investors.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.